Trial · NCT00884117
Results by group243
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 243
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Genotypic Resistance | Otherwise Healthy Participants Infected With Influenza | Baseline, H1N1 Seasonal (n=47) | 44 | participants | |
| Number of Participants With Genotypic Resistance | Otherwise Healthy Participants Infected With Influenza | Baseline, H1N1pdm09 (n=1240) | 1 | participants | |
| Number of Participants With Genotypic Resistance | Otherwise Healthy Participants Infected With Influenza | Baseline, H3N2 (n=1432) | 0 | participants | |
| Number of Participants With Genotypic Resistance | Otherwise Healthy Participants Infected With Influenza | Baseline, Influenza B (n=1006) | 2 | participants | |
| Number of Participants With Genotypic Resistance | Otherwise Healthy Participants Infected With Influenza | Baseline, All Types/Subtypes (n=3725) | 47 | participants | |
| Number of Participants With Genotypic Resistance | Otherwise Healthy Participants Infected With Influenza | Post-Baseline, H1N1 Seasonal (n=47) | 0 | participants | |
| Number of Participants With Genotypic Resistance | Otherwise Healthy Participants Infected With Influenza | Post-Baseline, H1N1pdm09 (n=1240) | 39 | participants | |
| Number of Participants With Genotypic Resistance | Otherwise Healthy Participants Infected With Influenza | Post-Baseline, H3N2 (n=1432) | 18 | participants | |
| Number of Participants With Genotypic Resistance | Otherwise Healthy Participants Infected With Influenza | Post-Baseline, Influenza B (n=1006) | 0 | participants | |
| Number of Participants With Genotypic Resistance | Otherwise Healthy Participants Infected With Influenza | Post-Baseline, All Types/Subtypes (n=3725) | 57 | participants | |
| Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections | Children <1 Year of Age Treated With Oseltamivir | Year 1, H3N2 (n=0,1,1,2,2,4) | NA | percentage of participants | |
| Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections | Children 1 to 5 Years of Age Treated With Oseltamivir | Year 1, H3N2 (n=0,1,1,2,2,4) | 0 | percentage of participants | |
| Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections | Children 6 to 12 Years of Age Treated With Oseltamivir | Year 1, H3N2 (n=0,1,1,2,2,4) | 0 | percentage of participants | |
| Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections | Children Treated With Oseltamivir | Year 1, H3N2 (n=0,1,1,2,2,4) | 0 | percentage of participants | |
| Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections | Adults Treated With Oseltamivir | Year 1, H3N2 (n=0,1,1,2,2,4) | 0 | percentage of participants | |
| Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections | Participants Treated With Oseltamivir | Year 1, H3N2 (n=0,1,1,2,2,4) | 0 | percentage of participants | |
| Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections | Children <1 Year of Age Treated With Oseltamivir | Year 2, H1N1pdm09 (n=0,54,81,135,108,243) | NA | percentage of participants | |
| Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections | Children 1 to 5 Years of Age Treated With Oseltamivir | Year 2, H1N1pdm09 (n=0,54,81,135,108,243) | 1.9 | percentage of participants | |
| Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections | Children 6 to 12 Years of Age Treated With Oseltamivir | Year 2, H1N1pdm09 (n=0,54,81,135,108,243) | 0 | percentage of participants | |
| Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections | Children Treated With Oseltamivir | Year 2, H1N1pdm09 (n=0,54,81,135,108,243) | 0.7 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00884117/results